Arqule Inc. (ARQL) 1.78 $ARQL Valeant (VRX) Stock Down

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 7:02 PM

Arqule Inc. (ARQL) 1.78 $ARQL

Valeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 10:24AM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) were down 14.6% after the company slashed its guidance for 2016 due to continued weakness across most of its business franchises.
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), VRX: 24.14 (-1.34), ARQL: 1.78 (unch)

Catalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 2:29PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 7 cents per share in the first quarter of 2016, which was wider than the year-ago loss of 6 cents but in line with the Zacks Consensus Estimate.
ABT: 38.40 (-0.47), CPRX: 0.62 (-0.03), SHPG: 177.10 (-6.85), ARQL: 1.78 (unch)

Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 37.14 (-0.37), ARQL: 1.78 (unch), APRI: 0.41 (-0.01), RPRX: 1.70 (-0.08)

Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 37.14 (-0.37), JAZZ: 150.76 (-5.26), ARQL: 1.78 (unch), APRI: 0.41 (-0.01)

BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.67 (-0.18), ENDP: 16.48 (-1.52), BSTC: 37.14 (-0.37), ARQL: 1.78 (unch)

ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:47AM CDT
ARIAD's (ARIA) decision to divest European operations should allow the company to focus on the U.S. market.
BSTC: 37.14 (-0.37), INCY: 80.41 (-1.20), ARQL: 1.78 (unch), ARIA: 8.27 (-0.15)

ArQule Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 6:00AM CDT
Conference call scheduled today at 9:00 a.m. ET
ARQL: 1.78 (unch)

Keryx (KERX) Q1 Loss in Line, Auryxia Up on Strong Demand (Revised)
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 12:30PM CDT
Keryx Biopharmaceuticals Inc.'s (KERX) first-quarter 2016 loss of 22 cents per share was in line with the Zacks Consensus Estimate.
SHPG: 177.10 (-6.85), ARQL: 1.78 (unch), AEGR: 1.37 (-0.13), KERX: 5.93 (-0.12)

ArQule To Report First Quarter 2016 Financial Results On May 4, 2016
GlobeNewswire - Wed Apr 20, 6:30AM CDT
ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the first quarter 2016 before the market opens on Wednesday, May 4, 2016. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update.
ARQL: 1.78 (unch)

Valeant (VRX) Receives Notice of Default: Stock in Trouble?
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 10:50AM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has received a notice of default from its debtors.
VRX: 24.14 (-1.34), ARQL: 1.78 (unch), SCMP: 11.70 (-0.27), AMAG: 21.04 (-0.82)

Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 2:35PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA's Gastrointestinal Drugs Advisory Committee has voted unanimously in favor of the company's lead pipeline candidate, Ocaliva.
ARQL: 1.78 (unch), SCMP: 11.70 (-0.27), ICPT: 150.66 (-3.56)

Intercept (ICPT) Up Ahead of Advisory Committee Meeting
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:10AM CDT
Shares of Intercept Pharmaceuticals, Inc. (ICPT) surged 13.3% just before the FDA Gastrointestinal Drug Advisory Committee's (GIDAC) meeting scheduled for Apr 7, 2016.
ECYT: 3.95 (-0.15), ARQL: 1.78 (unch), SCMP: 11.70 (-0.27), ICPT: 150.66 (-3.56)

Valeant Completes Accounting Review of Philidor, Shares Up
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:30AM CDT
Valeant Pharmaceuticals (VRX) announced that an accounting review related to Philidor, which was undertaken by the ad hoc committee appointed by the board of directors, has been completed witth no additional restatements required.
ECYT: 3.95 (-0.15), VRX: 24.14 (-1.34), ARQL: 1.78 (unch), SCMP: 11.70 (-0.27)

ArQule to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
GlobeNewswire - Tue Apr 05, 6:30AM CDT
ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 15 Annual Needham Healthcare Conference on April 12, 2016, at 2:20 p.m. ET at the Westin Grand Central Hotel in New York, New York.
ARQL: 1.78 (unch)

Keryx Up on Positive Auryxia Data in Iron Deficiency Anemia
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 2:20PM CDT
Shares of Keryx Biopharmaceuticals, Inc. (KERX) climbed 8.57% after the company announced positive top-line results from its phase III study on Auryxia (ferric citrate).
ARQL: 1.78 (unch), SCMP: 11.70 (-0.27), KERX: 5.93 (-0.12)

Valeant CEO Gets Subpoena from Senate Aging Committee
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:45PM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) dropped 7.2% after the company's CEO received a subpoena from the Senate Aging Committee amid the ongoing mess.
VRX: 24.14 (-1.34), ARQL: 1.78 (unch), SCMP: 11.70 (-0.27), CORT: 5.60 (+0.13)

Roche Files for FDA Approval of Elecsys BRAHMS Assay
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 8:30AM CDT
Roche Holdings, Inc. (RHHBY) announced that the company has submitted the Elecsys BRAHMS PCT (Procalcitonin) assay for Premarket Notification (510k) with the FDA
ARQL: 1.78 (unch), SCMP: 11.70 (-0.27), CORT: 5.60 (+0.13)

Valeant to Get a New CEO Amid Turmoil, Ackman on Board
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 11:40AM CDT
Valeant Pharmaceuticals International, Inc.'s (VRX) current chief executive officer (CEO) J. Michael Pearson has recently decided to step down.
VRX: 24.14 (-1.34), ARQL: 1.78 (unch), SCMP: 11.70 (-0.27), CORT: 5.60 (+0.13)

Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma
PR Newswire Europe - Tue Mar 22, 6:30AM CDT
Independent Data Monitoring Committee (DMC) Conducts Interim Assessment
ARQL: 1.78 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Jacobite Steam Train Redefines the Harry Potter Experience

Turn Fantasy into Reality: A Ride Unlike Any Other Ever fantasized about stepping right into the pages of your favorite tale? Well, the Jacobite Steam Train gives Potterheads just that: a literal ride through Harry Potter’s world, but in the heart of Scotland. As HBO's fresh take on the Harry Potter series is about to drop this Christmas, the buzz is lining the tracks...

Jill De Forest Honored: A Journey Through Recruitment

A Force in Recruitment: Jill De Forest There's a name that reverberates through the corridors of executive search and recruitment: Jill De Forest. Recognized by The Inner Circle as the Pinnacle Professional of The Year, De Forest has left a profound mark on the industry with her knack for matching exceptional talent to major brands. Trailblazing through Executive Search...

Meijer Team Gives Fuels Midwest Nonprofits: $3M Impact

Power to the Team: Meijer Makes Big Moves On any ordinary day, you'd see folks in Grand Rapids, Michigan, bustling about their routines, but today packs a different vibe. Meijer, the retailer that's been around the block a few times, is handing over a serious chunk of change to the tune of $3 million. This ain't just some half-hearted corporate stunt. Nope, this is the...

HANGCHA's AI-Fork Revolution: Bold Steps to 2030

Forklifts and the Future: A Fork in the Road for HANGCHA There's a movement happening, folks, and I don't mean in the usual stock ticker shift way. We're talking forklifts here—AI-powered, no less. HANGCHA Group, a name that may or may not roll off the tongue but sure makes waves in manufacturing, just held its 4th Global Dealers Conference in Hangzhou, China. If you're...

SEEKINK Dazzles with Game-Changing ePaper Innovations

A New Dawn for ePaper Technology In the whirlwind of the Electronica 2026 expo in Munich, it wasn’t some Silicon Valley juggernaut, but SEEKINK and TOPTE making headlines with their cutting-edge ePaper innovations. These folks may be quiet players, but with hall fans stirred and tongues wagging at Hall B6 Booth 518, they're changing the game in sustainable display tech....

Wood Partners Commences on 301-Unit Alta Meadowlands

Planting the Seeds for Alta Meadowlands It's all systems go for Wood Partners and GrayCo as they kick off construction on Alta Meadowlands in Hillsborough, North Carolina. Now, this isn't just another boxy warehouse masquerading as an apartment complex. We're talking a real commitment to shaking up the local real estate scene—a 301-unit community right in the...

NYSE Salutes Veterans and Shares Market Insights

Honoring Veterans at the NYSE It's not every day you see the hustle and bustle of the NYSE pause for a moment of reflection, but Veterans Day is one of those rare occasions. Before traders dive into the chaos of buying and selling, there's a solemn recognition of those who've soldiered on for our freedoms—a refreshing pause, if you ask me. As Brigadier General Matthew...

Victaulic's Top Honors for Supporting Reservists

Victaulic's latest accolade isn't just some badge to hang on the wall. This 5 STAR rating from Friendly Forces is a testament to a rock-solid commitment that goes way beyond lip service. It's about real backing for the Reservists who often juggle dual lives—combining military demands with civilian careers. Backing Reservists: Victaulic Steps Up Big When you look at how...

Yeastar 2026 Summit: AI, Growth, and Global Vision

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

Alyssa Bunch: Big Moves in Tennessee Real Estate

Navigating the Tennessee Real Estate Maze If you're talking about where the real estate action happens in Tennessee, you'd better mention Alyssa Bunch, the Vanderbilt-educated dynamo who turns the unforsale into the must-buy. Most of the deals she orchestrates are invisible to the public eye until they're all but written in ink and ready to reshape landscapes—or, more...